Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-04
2005-10-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S381000, C544S391000
Reexamination Certificate
active
06951862
ABSTRACT:
Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
REFERENCES:
patent: 3288795 (1966-11-01), Irikura et al.
patent: 4188485 (1980-02-01), Kukla
patent: 4918073 (1990-04-01), Ruger et al.
patent: 5386025 (1995-01-01), Jay et al.
patent: 5428038 (1995-06-01), Chatterjee et al.
patent: 5623051 (1997-04-01), Catterall et al.
patent: 5646149 (1997-07-01), Hellberg et al.
patent: 5703071 (1997-12-01), Itoh et al.
patent: 5866574 (1999-02-01), Okamura et al.
patent: 6011035 (2000-01-01), Snutch et al.
patent: 6294533 (2001-09-01), Snutch et al.
patent: 6310059 (2001-10-01), Snutch
patent: 6387897 (2002-05-01), Snutch
patent: 6458781 (2002-10-01), Connor et al.
patent: 6492375 (2002-12-01), Snutch
patent: 2001/0029258 (2001-10-01), Snutch
patent: 2004/0034035 (2004-02-01), Snutch et al.
patent: 2335461 (1999-06-01), None
patent: 2394327 (2001-06-01), None
patent: 0 187 524 (1986-07-01), None
patent: 0 213 006 (1987-03-01), None
patent: 0 458387 (1991-11-01), None
patent: 0 496 691 (1992-07-01), None
patent: 504 202 (1983-01-01), None
patent: 514 167 (1983-04-01), None
patent: 8 304 135 (1983-05-01), None
patent: 8 305 343 (1983-07-01), None
patent: 920 416 (1963-03-01), None
patent: 1 513 883 (1978-06-01), None
patent: WO 94/14786 (1994-07-01), None
patent: WO 99/15129 (1999-04-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 00/01375 (2000-01-01), None
patent: WO 00/18402 (2000-04-01), None
patent: WO 00/37059 (2000-06-01), None
patent: WO 01/45709 (2001-06-01), None
patent: WO-01/49670 (2001-07-01), None
patent: WO-03/068759 (2003-08-01), None
International Search Report for PCT/CA2004/000535, mailed on Jul. 1, 2004, 5 pages.
Invitation to Pay Additional Fees for PCT/CA2004/000539, mailed on Sep. 2, 2004, 6 pages.
Bourinet et al., “Splicing of α1ASubunit Gene Generates Phenotypic Variants of P- and Q-Type Calcium Channels,” Nature Neuroscience (1999) 2:407-415.
Chiarini, A. et al., “1,4-Dihydropyridines Bearing a Pharmacophoric Fragment of Lidoflazine” Bioorg & Med Chemistry (1996) 4(10):1629-1635.
Cohan, S. et al., Annals of the New York Academy of Sciences (1991) 635:397-399.
Cribbs et al., “Cloning and Characterization of α1H from Human Heart, A Member of the T-Type Ca3+Channel Gene Family,” Circulation Research (1998) 83:103-109.
Database WPI Week 9711 Derwent Publications Ltd., London, GB; Abstract JP 09 003067, XP002133055 (Hisamitsu Pharm Co Ltd.) Jan. 7, 1997.
De Waard et al., “Structural and Functional Diversity of Voltage-Activated Calcium Channels,” ION CHANNELS (Narahashi, T. ed. Plenum Press, NY (1997) 4:41-87.
Dhainaut et al., J of Medicinal Chemistry (1992) 35:2481-2496.
Dooley, “Lomerizine Kanebo KK” Current Opinion In CPNS Investigational Drugs (1999) 1(1):116-125.
Dunlap et al., “Exocytotic Ca2+Channels in Mammalian Central Neurons,” Trends Neurosci (1995) 18:89-98.
Estep, K. et al., J of Medicinal Chemistry (1995) 38(14):2582-2595.
Galizzi et al., “Neuroleptics of the Diphenylbutylpiperidine Series are Potent Calcium Channel Inhibitors,” Proc Natl Acad Sci USA (1986) 83: 7513-7517.
Glamkowski, E. et al., J of Medicinal Chemistry (1977) 20(11):1485-1489.
Gould et al., “Antischizophrenic Drugs of the Diphenylbutylpiperidine Type Act as Calcium Channel Antagonists,” Proc Natl Acad Sci (1983) 80:5122-5125.
Grantham et al., “Fluspirilene Block of N-Type Calcium Current in NGF-Differentiated PC12 Cells,” Brit J Pharmacol (1994) 111:438-488.
Ito et al., “U-92032, a T-Type Ca2+Channel Blocker and Antioxidant, Reduces Neuronal Ischemic Injuries,” Eur J Pharmacol (1994) 257:203-210.
King et al., “Substituted Diphenylbutylpiperidines Bind to a Unique High Affinity Site on the L-Type Calcium Channel,” J Biol Chem (1989) 264:5633-5641.
Lee et al., “Cloning and Expression of a Novel Member of the Low Voltage-Activated T-Type Calcium Channel Family,” Journal of Neuroscience (1999) 19:1912-1921.
Lehmann et al., Archiv der Pharmazie (1988) 321(11):807-812.
McCleskey et al., “Functional Properties of Voltage Dependent Calcium Channels,” Curr Topics Membr (1991) 39:295-326.
Miyano, S. et al., Chem Pharm Bull (1990) 38(6):1570-1574.
Ohtaka, H. et al., Chem Pharm Bull (1987) 35(10):4117-4123.
Ohtaka, H. et al., Chem Pharm Bull (1987) 35(8):3270-3275.
Perez-Reyes et al., “Molecular Characterization of a Neuronal Low-Voltage-Activated T-Type Calcium Channel,” Nature (1998) 391:896-900.
Prasad, R. et al., J of Medicinal Chemistry (1968) 11(6): 1144-1150.
Sather et al., “Distinctive Biophysical and Pharmacological Properties of Class A (BI) Calcium Channel α1Subunits,” Neuron (1993) 11:291-303.
Stea et al., “Localization and Functional Properties of a Rat Brain α1ACalcium Channel Reflect Similarities to Neuronal Q- and P-Type Channels,” Proc Natl Acad Sci USA (1994) 91:10576-10580.
Stea et al., Handbook of Receptors and Channels (North, R.A. ed. CRC Press (1995) 113-151.
Tytgat, J. et al., Brain Research (1991) 549(1):112-117.
Uneyama, H. et al., Calcium Ion Modulators, Sel Pap Satell Symp (1998) 13-23.
Vadodaria, D. et al., J of Medicinal Chemistry (1969) 12:860-865.
Zikolova, S. et al., Tr. Nauchnoizsled Khim-Farm Inst (1972) 8:59-67.
Zikolova, S. et al., Tr. Nauchnoizsled Khim-Farm Inst (1984) 14:23-28.
Boger et al., Helvetica Chimica Acta (2000) 83(8):1825-1845.
International Search Report for PCT/CA2004/001629, mailed on Jan. 21, 2005, 6 pages.
International Search Report for PCT/CA2004/000539, mailed on Dec. 22, 2004, 9 pages.
Jamieson et al., Synlett (2000) 11:1603-1607.
Toldy et al., Acta Chimica Academiae Scientiarum Hungarica (1965) 44:301-325.
Webster et al., Journal of the Chemical Society (2001) 14:1673-1695.
Belardetti Francesco
Pajouhesh Hassan
Pajouhesh Hossein
Snutch Terrance P.
Zamponi Gerald W.
Henley III Raymond J.
Neuromed Technologies, Inc.
LandOfFree
Calcium channel blockers comprising two benzhydril moieties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium channel blockers comprising two benzhydril moieties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium channel blockers comprising two benzhydril moieties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3481784